Avalon GloboCare ( ) - 株価, ニュースと分析Nasdaq:ALBT

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ALBT 株式概要

アバロン・グロボケア・コーポレーションはその子会社とともに、米国で商業用不動産物件を所有・運営している。

ALBT ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	2/6
配当金	0/6

報酬

リスク分析

意味のある時価総額がありません ( $5M )

収益が 100 万ドル未満 ( $-7M )

過去1年間で株主の希薄化は大幅に進んだ

過去3か月間の株価の変動は非常に激しい

Avalon GloboCare Corp. 競合他社

Ucommune International

NasdaqCM:UK

US$1.8m

Tuxis

OTCPK:TUXS

US$2.6m

New Concept Energy

NYSEAM:GBR

US$6.1m

Zoned Properties

OTCPK:ZDPY

US$6.2m

価格と性能

の歴代最高値、変動、値下がりまとめAvalon GloboCare
過去の株価
現在の株価	US$0.22
52週高値	US$1.44
52週安値	US$0.19
ベータ	0.31
11ヶ月の変化	-13.20%
3ヶ月変化	-55.62%
1年変化	-71.07%
33年間の変化	-97.77%
5年間の変化	-98.64%
IPOからの変化	-96.90%

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

株主還元

	ALBT	US Real Estate	US 市場
7D	-4.4%	0.4%	1.1%
1Y	-71.1%	30.0%	32.2%

業界別リターン: ALBT過去 1 年間で10.4 % の収益を上げたUS Real Estate業界を下回りました。

リターン対市場: ALBTは、過去 1 年間で24.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is ALBT's price volatile compared to industry and market?
ALBT volatility
ALBT Average Weekly Movement	29.6%
Real Estate Industry Average Movement	7.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.7%
10% least volatile stocks in US Market	3.1%

安定した株価: ALBTの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ALBTの週次ボラティリティは過去 1 年間で49%から31%に減少しましたが、依然としてUS株の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2016	5	David Jin	www.avalon-globocare.com

Avalon GloboCare Corp.はその子会社とともに、米国で商業用不動産を所有・運営している。同社は、精密診断資産、遺伝子検査、合弁事業による臨床検査会社の所有権取得またはライセンス権、株式所有構造または販売権を通じて、診断および臨床検査サービスの開発に注力している。同社は2016年に設立され、ニュージャージー州フリーホールドに本社を置いている。

Avalon GloboCare Corp. 基礎のまとめ

Avalon GloboCare の収益と売上を時価総額と比較するとどうか。
ALBT 基礎統計学
時価総額	US$3.47m
収益（TTM）	-US$14.54m
売上高(TTM)	n/a

-0.5x

P/Sレシオ

-0.2x

PER（株価収益率

ALBT は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ALBT 損益計算書（TTM）
収益	-US$7.53m
売上原価	US$1.07m
売上総利益	-US$8.60m
その他の費用	US$5.94m
収益	-US$14.54m

直近の収益報告

Jun 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-0.91
グロス・マージン	114.24%
純利益率	193.04%
有利子負債／自己資本比率	185.5%

ALBT の長期的なパフォーマンスは？

過去の実績と比較を見る

ALBT 株式概要

報酬

リスク分析

Avalon GloboCare Corp. 競合他社

NasdaqCM:UK

US$1.8m

OTCPK:TUXS

US$2.6m

NYSEAM:GBR

US$6.1m

OTCPK:ZDPY

US$6.2m

価格と性能

最新ニュース

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Recent updates

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54

First half earnings released

株主還元